β-blockers reduce the incidence of clinical restenosis: Prospective study of 4840 patients undergoing percutaneous coronary revascularization

American Heart Journal

Volumn 145, Issue 5, 2003, Pages 875-881

  Jackson, Jeffrey D ^a,b   Muhlestein, Joseph B ^a,b   Bunch, T Jared ^b   Bair, Tami L ^a   Horne, Benjamin D ^a   Madsen, Troy E ^a   Lappé, Jason M ^a   Anderson, Jeffrey L ^a,b  

^a LDS HOSPITAL   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ADULT; AGED; ARTICLE; ATHERECTOMY; CELL PROLIFERATION; CORONARY ARTERY DISEASE; CORONARY RISK; DRUG MECHANISM; FEMALE; HEART MUSCLE REVASCULARIZATION; HEART VENTRICLE REMODELING; HEMODYNAMIC MONITORING; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESTENOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0038742086     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(02)94726-5     Document Type: Article

References (28)

1. Serruys PW, Luijten HE, Beatt K J, et al. Incidence of restenosis after successful coronary angioplasty: a time-related phenomenon. Circulation 1988;77:361-71.
2. Holmes DR, Vlietstra RE, Smith HC, et al. Restenosis after percutaneous transluminal coronary angioplasty: a report from the PCI registry of the National Heart, Lung, and Blood Institute. Am J Cardiol 1984;53:77-81C.
3. Nobuyoshi M, Kimura T, Nosaka H, et al. Restenosis after successful percutaneous transluminal coronary angioplasty: serial angiographic follow-up of 299 patients. J Am Coll Cardiol 1988;12:616-23.
4. Voisard R, Dartsch PC, Seitzer U, et al. Cell culture as a prescreening system for drug prevention of restenosis? Vasa 1991;33(Suppl):140-1.
5. Johansson SR, Lamm C, Bondjers G, et al. Role of β-adrenergic blockers after percutaneous transluminal coronary angioplasty. Am J Cardiol 1990;66:915-20.
6. Serruys PW, Foley DP, Hofling B, et al. Carvedilol for prevention of restenosis after directional coronary atherectomy. Circulation 2000;101:1512-8.
7. Anonymous. Myocardial infarction and mortality in the coronary artery surgery study (CASS) randomized trial. N Engl J Med 1984;310:750-8.
8. Rodriguez A, Santaera O, Larribeau M, et al. Early decrease in minimal luminal diameter after successful percutaneous transluminal coronary angioplasty predicts late restenosls. Am J Cardiol 1993;71:1391-5.
9. Cox JL, Gotlieb AI. Review of antiplatelet drug use in preventing restenosis following percutaneous transluminal coronary angioplasty. Can J Cardiol 1988;4:201-10.
10. Uchida Y, Hasegawa K, Kawamura K, et al. Angioscopic observation of the coronary luminal changes induced by coronary angioplasty. Am Heart J 1989;117:769-76.
11. Ip JH, Fuster V, Israel D, et al. The role of platelets, thrombin and hyperplasia in restenosis after coronary angioplasty. J Am Coll Cardiol 1991;17:77-8B.
12. Willerson JT, McNatt J, Yao SK, et al. Pretreatment with antagonists to thromboxane-A(2), serotonin and ADP reduces neointimal proliferation in canine coronary arteries after endothelial injury. J Am Coll Cardiol 1994;23(Suppl):A234.
13. Casscells W. Migration of smooth muscle and endothelial cells: critical events in restenosis. Circulation 1992;86:723-9.
14. Strauss BH, Chisholm RJ, Keeley FW, et al. Extracellular matrix remodeling after balloon angioplasty injury in a rabbit model of restenosis. Circ Res 1994;75:650-8.
15. Riessen R, Isner JM, Blessing E, et al. Regional differences in the distribution of the proteoglycans biglycan and decorin in the extra-celluar matrix of atherosclerotic and restenotic human coronary arteries. Am J Pathol 1994;144:962-74.
16. Libby P, Tanaka H. The molecular basis of restenosis and clinical study of restenosis. Prog Cardiovasc Dis 1997;40:97-106.
17. Wikstrand J, Warnold I, Olsson G, et al. Primary prevention with metoprolol in patients with hypertension: mortality results from the MAPHY study. JAMA 1988;259:1976-82.
18. Teo KK, Yusuf S, Furberg CD. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. JAMA 1993;270:1589-95.
19. Brodsky MA, Allen BJ, Luckett CR, et al. Antiarrhythmic efficacy of solitary beta-adrenergic blockade for patients with sustained ventricular tachyarrhythmias. Am Heart J 1989;118:272-80.
20. Daudon P, Corcos T, Gandjbakhch I, et al. Prevention of atrial fibrillation or flutter by acebutolol after coronary bypass grafting. Am J Cardiol 1986;58:933-6.
21. Doughty RN, MacMahon S, Sharpe N. Beta-blockers in heart failure: promising or proved? J Am Coll Cardiol 1994;23:814-82.
22. Andersson B, Hamm C, Persson S, et al. Improved exercise hemodynamic status in dilated cardiomyopathy after beta-adrenergic blockade treatment. J Am Coll Cardiol 1994;23:1397-404.
23. Kaplan JR, Petterson K, Manuck SB, et al. Role of sypathoadrenal medullary activation in the initiation and progression of atherosclerosis. Circulation 1991;84(6 Suppl):VI-23-32.
24. Winther K, Willich SN. β1-Blockade and acute coronary ischemia: possible role of platelets. Circulation 1991;84(6 Suppl):VI-68-71.
25. Hjemdahl P, Larsson PT, Wallen NH. Effects of stress and beta-blockade on platelet function. Circulation 1991;84(6 Suppl):VI-44-61.
26. Campbell WB, Callahan K, Johnson AR, et al. Antiplatelet activity of beto-adrenergic antagonist: inhibition of thromboxane synthesis and platelet aggregation in patients receiving long-term propranolol treatment. Lancet 1981;2:1382-4.
27. Shores J, Berger KR, Murphy EA, et al. Progression of aortic dilation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome. N Engl J Med 1994;330:1335-41.
28. Douglas SA, Vickery-Clark LM, Louden C, et al. Acute pretreatment with carvedilol is sufficient for inhibition of neointima formation following rat carotid artery balloon angioplasty. Pharmacol Res Commun 1994;5:65-72.